FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2377774447> ?p ?o ?g. }

• W2377774447 endingPage "1194" @default.
• W2377774447 startingPage "1188" @default.
• W2377774447 abstract "•Management of familial hypercholesterolemia (FH) is challenging in developing nations. •Complex treatments require innovative approaches to funding and delivery. •New drug therapies for FH may contribute to overcoming these challenges. Background Familial hypercholesterolemia (FH) leads to premature coronary artery disease and aortic stenosis, with undertreated severe forms causing death at a young age. Lipoprotein apheresis (LA) is often required for lowering low-density lipoprotein cholesterol levels in severe FH. Objectives The objective of this study was to present the first experiences with LA in Malaysia, between 2004 and 2014. Methods We retrospectively collected data from patient records to assess the effectiveness, adverse effects, patient quality of life, and costs associated with an LA service for genetically confirmed homozygous and heterozygous FH. Results We treated 13 women and 2 men aged 6 to 59 years, 10 with homozygous and 5 with heterozygous FH, all on maximally tolerated cholesterol-lowering drug therapy, for a total of 65 patient-years. Acute lowering of low-density lipoprotein cholesterol post apheresis was 56.3 ± 7.2%, with time-averaged mean lowering of 34.9 ± 13.9%. No patients experienced any cardiovascular events during the period of receiving LA. Patients receiving LA experienced few side effects and enjoyed reasonable quality of life, but inability to continue treatment was frequent because of cost. Conclusion LA for severe FH can be delivered effectively in the short term in developing nations, but costs are a major barrier to sustaining this mode of treatment for this high-risk group of patients. New drug therapies for FH, such as the proprotein convertase subtilisin/kexin type 9 inhibitors, microsomal triglyceride transfer protein inhibitors, and apolipoprotein-B100 antisense oligonucleotides may allow improved care for these patients, but costs and long-term safety remain as issues to be addressed. Familial hypercholesterolemia (FH) leads to premature coronary artery disease and aortic stenosis, with undertreated severe forms causing death at a young age. Lipoprotein apheresis (LA) is often required for lowering low-density lipoprotein cholesterol levels in severe FH. The objective of this study was to present the first experiences with LA in Malaysia, between 2004 and 2014. We retrospectively collected data from patient records to assess the effectiveness, adverse effects, patient quality of life, and costs associated with an LA service for genetically confirmed homozygous and heterozygous FH. We treated 13 women and 2 men aged 6 to 59 years, 10 with homozygous and 5 with heterozygous FH, all on maximally tolerated cholesterol-lowering drug therapy, for a total of 65 patient-years. Acute lowering of low-density lipoprotein cholesterol post apheresis was 56.3 ± 7.2%, with time-averaged mean lowering of 34.9 ± 13.9%. No patients experienced any cardiovascular events during the period of receiving LA. Patients receiving LA experienced few side effects and enjoyed reasonable quality of life, but inability to continue treatment was frequent because of cost. LA for severe FH can be delivered effectively in the short term in developing nations, but costs are a major barrier to sustaining this mode of treatment for this high-risk group of patients. New drug therapies for FH, such as the proprotein convertase subtilisin/kexin type 9 inhibitors, microsomal triglyceride transfer protein inhibitors, and apolipoprotein-B100 antisense oligonucleotides may allow improved care for these patients, but costs and long-term safety remain as issues to be addressed." @default.
• W2377774447 created "2016-06-24" @default.
• W2377774447 creator A5044528819 @default.
• W2377774447 creator A5058981266 @default.
• W2377774447 creator A5067704164 @default.
• W2377774447 creator A5079564889 @default.
• W2377774447 creator A5087008130 @default.
• W2377774447 date "2016-09-01" @default.
• W2377774447 modified "2023-10-14" @default.
• W2377774447 title "Ten years of lipoprotein apheresis for familial hypercholesterolemia in Malaysia: A creative approach by a cardiologist in a developing country" @default.
• W2377774447 cites W1986322454 @default.
• W2377774447 cites W1987344094 @default.
• W2377774447 cites W1991671549 @default.
• W2377774447 cites W1992969017 @default.
• W2377774447 cites W2002659211 @default.
• W2377774447 cites W2004683380 @default.
• W2377774447 cites W2011680209 @default.
• W2377774447 cites W2016805353 @default.
• W2377774447 cites W2029650652 @default.
• W2377774447 cites W2037458235 @default.
• W2377774447 cites W2042489459 @default.
• W2377774447 cites W2051679035 @default.
• W2377774447 cites W2058652637 @default.
• W2377774447 cites W2066764702 @default.
• W2377774447 cites W2069925045 @default.
• W2377774447 cites W2088794717 @default.
• W2377774447 cites W2131070472 @default.
• W2377774447 cites W68591543 @default.
• W2377774447 doi "https://doi.org/10.1016/j.jacl.2016.05.006" @default.
• W2377774447 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27678436" @default.
• W2377774447 hasPublicationYear "2016" @default.
• W2377774447 type Work @default.
• W2377774447 sameAs 2377774447 @default.
• W2377774447 citedByCount "14" @default.
• W2377774447 countsByYear W23777744472017 @default.
• W2377774447 countsByYear W23777744472018 @default.
• W2377774447 countsByYear W23777744472019 @default.
• W2377774447 countsByYear W23777744472021 @default.
• W2377774447 countsByYear W23777744472022 @default.
• W2377774447 crossrefType "journal-article" @default.
• W2377774447 hasAuthorship W2377774447A5044528819 @default.
• W2377774447 hasAuthorship W2377774447A5058981266 @default.
• W2377774447 hasAuthorship W2377774447A5067704164 @default.
• W2377774447 hasAuthorship W2377774447A5079564889 @default.
• W2377774447 hasAuthorship W2377774447A5087008130 @default.
• W2377774447 hasConcept C126322002 @default.
• W2377774447 hasConcept C159110408 @default.
• W2377774447 hasConcept C187212893 @default.
• W2377774447 hasConcept C197934379 @default.
• W2377774447 hasConcept C2776738589 @default.
• W2377774447 hasConcept C2778163477 @default.
• W2377774447 hasConcept C2778213512 @default.
• W2377774447 hasConcept C2778751355 @default.
• W2377774447 hasConcept C2779120738 @default.
• W2377774447 hasConcept C2779951463 @default.
• W2377774447 hasConcept C71924100 @default.
• W2377774447 hasConcept C89560881 @default.
• W2377774447 hasConceptScore W2377774447C126322002 @default.
• W2377774447 hasConceptScore W2377774447C159110408 @default.
• W2377774447 hasConceptScore W2377774447C187212893 @default.
• W2377774447 hasConceptScore W2377774447C197934379 @default.
• W2377774447 hasConceptScore W2377774447C2776738589 @default.
• W2377774447 hasConceptScore W2377774447C2778163477 @default.
• W2377774447 hasConceptScore W2377774447C2778213512 @default.
• W2377774447 hasConceptScore W2377774447C2778751355 @default.
• W2377774447 hasConceptScore W2377774447C2779120738 @default.
• W2377774447 hasConceptScore W2377774447C2779951463 @default.
• W2377774447 hasConceptScore W2377774447C71924100 @default.
• W2377774447 hasConceptScore W2377774447C89560881 @default.
• W2377774447 hasIssue "5" @default.
• W2377774447 hasLocation W23777744471 @default.
• W2377774447 hasLocation W23777744472 @default.
• W2377774447 hasOpenAccess W2377774447 @default.
• W2377774447 hasPrimaryLocation W23777744471 @default.
• W2377774447 hasRelatedWork W1964923049 @default.
• W2377774447 hasRelatedWork W2003447000 @default.
• W2377774447 hasRelatedWork W2016290144 @default.
• W2377774447 hasRelatedWork W2036708012 @default.
• W2377774447 hasRelatedWork W2047344526 @default.
• W2377774447 hasRelatedWork W2342015650 @default.
• W2377774447 hasRelatedWork W2413360451 @default.
• W2377774447 hasRelatedWork W2444087174 @default.
• W2377774447 hasRelatedWork W2626008064 @default.
• W2377774447 hasRelatedWork W77371887 @default.
• W2377774447 hasVolume "10" @default.
• W2377774447 isParatext "false" @default.
• W2377774447 isRetracted "false" @default.
• W2377774447 magId "2377774447" @default.
• W2377774447 workType "article" @default.